Page last updated: 2024-11-04

rolipram and Asthma

rolipram has been researched along with Asthma in 46 studies

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to evaluate the influence of pretreatment with the phosphodiesterase-4 inhibitor rolipram on pulmonary resistance, influx of inflammatory cells, and histamine concentration in bronchoalveolar lavage fluid (BALF) during an experimental asthmatic reaction induced in ovalbumin (OA)-sensitized guinea pigs, challenged with OA inhalation."7.73Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. ( Chazan, R; Glapiński, J; Grubek-Jaworska, H; Hoser, G; Nejman-Gryz, P, 2006)
" Theophylline possesses anti-inflammatory activities in asthma."7.72Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. ( Chung, KF; Huang, KH; Kuo, HP; Lin, CH; Lin, HC; Liu, SL; Wang, CH; Yu, CT, 2003)
" Therefore, we were interested in investigating its selectivity on PDE4 and binding ability on high-affinity rolipram-binding sites (HARBs) in vitro, and its effects on ovalbumin-induced airway hyperresponsiveness in vivo, and clarifying its potential for treating asthma and chronic obstructive pulmonary disease (COPD)."3.77Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio. ( Chen, CM; Han, CY; Hsu, HT; Ko, WC; Wang, KH; Yang, YL, 2011)
"The aim of this study was to evaluate the influence of pretreatment with the phosphodiesterase-4 inhibitor rolipram on pulmonary resistance, influx of inflammatory cells, and histamine concentration in bronchoalveolar lavage fluid (BALF) during an experimental asthmatic reaction induced in ovalbumin (OA)-sensitized guinea pigs, challenged with OA inhalation."3.73Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. ( Chazan, R; Glapiński, J; Grubek-Jaworska, H; Hoser, G; Nejman-Gryz, P, 2006)
" Theophylline possesses anti-inflammatory activities in asthma."3.72Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. ( Chung, KF; Huang, KH; Kuo, HP; Lin, CH; Lin, HC; Liu, SL; Wang, CH; Yu, CT, 2003)
"The aim of this study was to establish a conscious guinea-pig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels."3.72Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram. ( Broadley, KJ; Toward, TJ, 2004)
"PBMCs from control subjects and allergic asthmatic patients were stimulated with PHA in the presence of low doses of fluticasone propionate (FP) with or without salmeterol for 72 hours."3.72Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists. ( Dunlap, A; Goleva, E; Leung, DY, 2004)
" Selected compounds have also been examined for their activities in inhibiting histamine-induced bronchospasm in anaesthetized guinea pigs."3.69Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. ( Ashton, MJ; Cook, DC; Fenton, G; Karlsson, JA; Palfreyman, MN; Raeburn, D; Ratcliffe, AJ; Souness, JE; Thurairatnam, S; Vicker, N, 1994)
"A new guinea pig model of allergic asthma was used to investigate the effects of low doses of the phosphodiesterase inhibitors, rolipram (phosphodiesterase IV selective), ORG 20241 (N-hydroxy-4-(3,4-dimethoxyphenyl)-thiazole-2-carboximidamide; dual phosphodiesterase III/IV inhibitor with some selectivity for the phosphodiesterase IV isoenzyme), and of theophylline (non-selective) on allergen-induced early and late phase asthmatic reactions, bronchial hyperreactivity to histamine inhalation, and airway inflammation."3.69Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. ( Meurs, H; Olymulder, CG; Santing, RE; Van der Molen, K; Zaagsma, J, 1995)
"The effect of rolipram, an isozyme IV-selective inhibitor of cAMP-specific phosphodiesterase, was evaluated in a guinea pig eye model of tissue eosinophilia."3.68cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva. ( Newsholme, SJ; Schwartz, L, 1993)
"Theophylline has been widely used in the treatment of bronchial asthma mainly due to its bronchodilating effect."1.32Theophylline attenuates the adhesion of eosinophils to endothelial cells. ( Choo, JH; Kikuchi, I; Nagata, M; Sakamoto, Y; Sutani, A, 2003)
" Multiple day dosing also improved activity."1.31Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. ( Egging, EA; Gullikson, GW; Hammerbeck, DM; Hupperts, AM; Johnson, DD; McGurran, SM; Radziszewski, PL, 2000)
"Rolipram was characterized for its emetic, behavioral, cardiovascular and pulmonary activities in dogs, to assess its systemic pharmacology and potential bronchodilatory selectivity."1.29Emetic, central nervous system, and pulmonary activities of rolipram in the dog. ( Evans, DY; Heaslip, RJ, 1995)
"Pretreatment with rolipram (10 mg kg-1, i."1.29Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs. ( Cortijo, J; Martí-Cabrera, M; Morcillo, EJ; Ortiz, JL; Vallés, JM, 1996)
"Treatment with rolipram, but not theophylline, prevented the increase in responsiveness to inhaled histamine 24 h after antigen challenge."1.29Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits. ( Blake, SM; Gozzard, N; Herd, CM; Higgs, GA; Holbrook, M; Hughes, B; Page, CP, 1996)
"4."1.29The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. ( Alexander, R; Allen, R; Blease, K; Bloxham, D; Boyd, E; Catterall, C; Eaton, M; Gozzard, N; Head, J; Higgs, G; Holbrook, M; Howat, D; Hughes, B; Hughes, P; James, T; Kingaby, R; Lisle, H; Lumb, S; Merriman, M; Owens, R; Perry, M; Russell, A; Smith, B; Wales, M; Warrellow, G, 1996)

Research

Studies (46)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's14 (30.43)18.2507
2000's23 (50.00)29.6817
2010's9 (19.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ashton, MJ1
Cook, DC1
Fenton, G1
Karlsson, JA1
Palfreyman, MN1
Raeburn, D1
Ratcliffe, AJ1
Souness, JE2
Thurairatnam, S1
Vicker, N1
Hersperger, R1
Bray-French, K1
Mazzoni, L1
Müller, T1
Buckley, G1
Cooper, N2
Dyke, HJ2
Galleway, F1
Gowers, L2
Gregory, JC1
Hannah, DR1
Haughan, AF2
Hellewell, PG1
Kendall, HJ2
Lowe, C2
Maxey, R2
Montana, JG2
Naylor, R2
Picken, CL2
Runcie, KA2
Sabin, V2
Tuladhar, BR1
Warneck, JB2
Buckley, GM1
Galleway, FP1
Oxford, J1
Peake, JC1
Sharpe, A1
Kodimuthali, A1
Jabaris, SS1
Pal, M1
Kato, Y1
Kawasaki, M2
Nigo, T2
Nakamura, S2
Fusano, A2
Teranishi, Y2
Ito, MN2
Sumiyoshi, T2
Matsumoto, S1
Toda, H1
Nomura, N1
Song, G1
Zhu, X1
Li, J1
Hu, D1
Zhao, D1
Liao, Y1
Lin, J1
Zhang, LH2
Cui, ZN2
Hu, DK1
Zhao, DS1
He, M1
Jin, HW1
Tang, YM1
Song, GP1
Schymeinsky, J1
Mayer, H1
Tomsic, C1
Tilp, C1
Schuetz, JD1
Cui, Y1
Wollin, L1
Gantner, F1
Erb, KJ1
Park, K1
Lee, JS1
Choi, JS1
Nam, YJ1
Han, JH1
Byun, HD1
Song, MJ1
Oh, JS1
Kim, SG1
Choi, Y1
Yougbare, I1
Morin, C1
Senouvo, FY1
Sirois, C1
Albadine, R1
Lugnier, C1
Rousseau, E1
Yang, YL1
Hsu, HT1
Wang, KH1
Han, CY1
Chen, CM2
Ko, WC1
Kenk, M1
Thomas, A1
Lortie, M1
Dekemp, R1
Beanlands, RS1
Dasilva, JN1
Wang, CH1
Lin, HC1
Lin, CH1
Yu, CT1
Liu, SL1
Huang, KH1
Chung, KF1
Kuo, HP1
Choo, JH1
Nagata, M1
Sutani, A1
Kikuchi, I1
Sakamoto, Y1
Toward, TJ1
Broadley, KJ1
Goleva, E1
Dunlap, A1
Leung, DY1
Tang, HF1
Song, YH1
Chen, JC1
Chen, JQ1
Wang, P1
Jones, NA2
Leport, M1
Holand, T1
Vos, T1
Morgan, M1
Fink, M1
Pruniaux, MP1
Berthelier, C1
O'Connor, BJ3
Bertrand, C1
Page, CP4
Nejman-Gryz, P2
Grubek-Jaworska, H2
Glapiński, J1
Hoser, G1
Chazan, R2
Glapińiski, J1
Edwards, MR1
Haas, J1
Panettieri, RA1
Johnson, M1
Johnston, SL1
Hu, A1
Nino, G1
Grunstein, JS1
Fatma, S1
Grunstein, MM1
Nicholson, CD1
Shahid, M1
Bruin, J1
Barron, E1
Spiers, I1
de Boer, J1
van Amsterdam, RG1
Zaagsma, J2
Kelly, JJ1
Dent, G2
Torphy, TJ2
Barnette, MS1
Hay, DW1
Underwood, DC1
Lagente, V1
Hichami, A1
Boichot, E1
Martins, MA1
Silva, PM1
Santing, RE1
Olymulder, CG1
Van der Molen, K1
Meurs, H1
Newsholme, SJ1
Schwartz, L1
Cortijo, J2
Bou, J1
Beleta, J1
Cardelús, I1
Llenas, J1
Morcillo, E1
Gristwood, RW1
Heaslip, RJ1
Evans, DY1
Ortiz, JL1
Vallés, JM1
Martí-Cabrera, M1
Morcillo, EJ1
Gozzard, N3
Herd, CM1
Blake, SM1
Holbrook, M2
Hughes, B3
Higgs, GA1
Howat, D1
Lisle, H1
James, T1
Blease, K1
Hughes, P1
Kingaby, R1
Warrellow, G1
Alexander, R1
Head, J1
Boyd, E1
Eaton, M1
Perry, M2
Wales, M2
Smith, B1
Owens, R1
Catterall, C1
Lumb, S1
Russell, A1
Allen, R1
Merriman, M1
Bloxham, D1
Higgs, G2
Foissier, L1
Lonchampt, M1
Cogé, F1
Canet, E1
Manabe, H2
Akuta, K2
Okamura, K1
Ohmori, K2
Hidi, R1
Timmermans, S1
Liu, E1
Schudt, C1
Holgate, ST1
Djukanović, R1
Kawasaki, H1
Hammerbeck, DM1
McGurran, SM1
Radziszewski, PL1
Egging, EA1
Johnson, DD1
Hupperts, AM1
Gullikson, GW1
Pang, L1
Knox, AJ1
Dal Piaz, V1
Giovannoni, MP1
Landells, LJ2
Spina, D2
Szilagy, CM1
Banner, KH1
Allen, JM1
Doherty, A1
Yoshida, N1
Shimizu, Y1
Kitaichi, K1
Hiramatsu, K1
Takeuchi, M1
Ito, Y1
Kume, H1
Yamaki, K1
Suzuki, R1
Shibata, E1
Hasegawa, T1
Takagi, K1
Alexander, RP1
Warrellow, GJ1
Eaton, MA1
Boyd, EC1
Head, JC1
Porter, JR1
Brown, JA1
Reuberson, JT1
Hutchinson, B1
Turner, P1
Boyce, B1
Barnes, D1
Mason, B1
Cannell, A1
Taylor, RJ1
Zomaya, A1
Millican, A1
Leonard, J1
Morphy, R1
Allen, RA1
Livi, GP1
Balcarek, JM1
White, JR1
Chilton, FH1
Undem, BJ1

Reviews

4 reviews available for rolipram and Asthma

ArticleYear
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
    Journal of medicinal chemistry, 2008, Sep-25, Volume: 51, Issue:18

    Topics: Asthma; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chr

2008
PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
    Current radiopharmaceuticals, 2011, Volume: 4, Issue:1

    Topics: Animals; Asthma; Brain; Carbon Radioisotopes; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type

2011
Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
    European journal of medicinal chemistry, 2000, Volume: 35, Issue:5

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Arthritis, Rheumatoid; Asthma; Cyclic Nucleotide Phosphodiester

2000
Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma.
    Advances in second messenger and phosphoprotein research, 1992, Volume: 25

    Topics: 1-Methyl-3-isobutylxanthine; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Asthma; Colforsin;

1992

Other Studies

42 other studies available for rolipram and Asthma

ArticleYear
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
    Journal of medicinal chemistry, 1994, May-27, Volume: 37, Issue:11

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aorta; Asthma; Benzamides; Bronchial Spasm; Eosinophil

1994
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
    Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Anti-Asthmatic Agents; Asthma; B

2000
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
    Bioorganic & medicinal chemistry letters, 2000, Sep-18, Volume: 10, Issue:18

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Asthma; Benzamides; Benzofurans;

2000
8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
    Bioorganic & medicinal chemistry letters, 2002, Jun-17, Volume: 12, Issue:12

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amides; Anti-Asthmatic Agents; Asthma; Cyclic Nucleotide Phosph

2002
Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
    Bioorganic & medicinal chemistry, 2013, Sep-15, Volume: 21, Issue:18

    Topics: Animals; Anti-Inflammatory Agents; Asthma; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Mod

2013
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
    Bioorganic & medicinal chemistry letters, 2014, Jun-15, Volume: 24, Issue:12

    Topics: Administration, Oral; Asthma; Emetics; Enzyme Activation; Molecular Structure; Phosphodiesterase 4 I

2014
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
    Bioorganic & medicinal chemistry, 2017, 10-15, Volume: 25, Issue:20

    Topics: Animals; Asthma; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Drug Design;

2017
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
    Bioorganic & medicinal chemistry letters, 2018, 10-15, Volume: 28, Issue:19

    Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Inhibitory Concentration 50; Mice; Phosphodiesterase

2018
The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Adenosine; Allergens; Animals; Asthma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-

2013
Identification and Characterization of Baicalin as a Phosphodiesterase 4 Inhibitor.
    Phytotherapy research : PTR, 2016, Volume: 30, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Fla

2016
NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.
    American journal of physiology. Lung cellular and molecular physiology, 2011, Volume: 301, Issue:4

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Anti-Inflammatory Agents; Asthma

2011
Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.
    Journal of biomedical science, 2011, Nov-11, Volume: 18

    Topics: Animals; Asthma; Binding Sites; Blood Cell Count; Bronchial Hyperreactivity; Bronchoalveolar Lavage

2011
Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma.
    British journal of pharmacology, 2003, Volume: 138, Issue:6

    Topics: Albuterol; Animals; Antigens, CD34; Apoptosis; Asthma; Cell Division; Female; Humans; Male; Methacho

2003
Theophylline attenuates the adhesion of eosinophils to endothelial cells.
    International archives of allergy and immunology, 2003, Volume: 131 Suppl 1

    Topics: Adult; Asthma; Bronchodilator Agents; Cell Adhesion; Cyclic AMP; Endothelium, Vascular; Eosinophils;

2003
Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2004, Volume: 34, Issue:1

    Topics: Administration, Inhalation; Animals; Antigens; Asthma; Bronchial Hyperreactivity; Bronchoalveolar La

2004
Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists.
    The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Cell C

2004
Upregulation of phosphodiesterase-4 in the lung of allergic rats.
    American journal of respiratory and critical care medicine, 2005, Apr-15, Volume: 171, Issue:8

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Airway Resistance; Animals; Asthma; Cyclic Nucleotide Phosphodi

2005
Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
    Pulmonary pharmacology & therapeutics, 2007, Volume: 20, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Asthma; Benzamides; CD4-Positive T-Lymphocytes; CD

2007
Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2006, Volume: 57 Suppl 4

    Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Dexamethasone; Guinea Pigs;

2006
[Effect of phosphodiestrase 4 inhibitor (rolipram) on experimental allergic asthma-guinea pig model].
    Pneumonologia i alergologia polska, 2006, Volume: 74, Issue:1

    Topics: Administration, Inhalation; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar L

2006
Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements.
    The Journal of biological chemistry, 2007, May-25, Volume: 282, Issue:21

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agen

2007
Prolonged heterologous beta2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction.
    American journal of physiology. Lung cellular and molecular physiology, 2008, Volume: 294, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Animals; Asthma; Butadienes; Cells, Cultured; Colforsin; Cyclic

2008
Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
    The Journal of pharmacology and experimental therapeutics, 1995, Volume: 274, Issue:2

    Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Asthma; Cattle; Guinea Pigs; Humans; In Vitro T

1995
Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
    Environmental health perspectives, 1994, Volume: 102 Suppl 10

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antigens; Asthma; Bronchoconstriction; Cell Adhesion;

1994
Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
    Allergie et immunologie, 1995, Volume: 27, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Airway Resistan

1995
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
    European journal of pharmacology, 1995, Feb-24, Volume: 275, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Analysis of Variance; Animals; Asth

1995
cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva.
    Inflammation, 1993, Volume: 17, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Asthma; Conjunctiva; Conjunctivitis; Eosinophilia; Eos

1993
Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
    British journal of pharmacology, 1993, Volume: 108, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Animals; Asthma; Bronchodilator Agents; Cyclic Nuc

1993
Emetic, central nervous system, and pulmonary activities of rolipram in the dog.
    European journal of pharmacology, 1995, Nov-24, Volume: 286, Issue:3

    Topics: Animals; Anxiety; Asthma; Brain; Bronchi; Dogs; Female; Heart Rate; Male; Nadolol; Pentobarbital; Ph

1995
Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.
    Naunyn-Schmiedeberg's archives of pharmacology, 1996, Volume: 353, Issue:2

    Topics: Animals; Asthma; Dose-Response Relationship, Drug; Eosinophils; Guinea Pigs; Histamine; Male; Phosph

1996
Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits.
    British journal of pharmacology, 1996, Volume: 117, Issue:7

    Topics: Airway Resistance; Alternaria; Animals; Anti-Inflammatory Agents; Antigens, Fungal; Asthma; Bronchia

1996
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
    British journal of pharmacology, 1996, Volume: 118, Issue:5

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Airway Resistance; Analysis of Variance; Animals; Asthma; Benza

1996
In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
    The Journal of pharmacology and experimental therapeutics, 1996, Volume: 278, Issue:3

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antigens; Asthma; Cyclic AMP; Cyclic Nucleotide Phosph

1996
KF19514, a phosphodieterase 4 and 1 inhibitor, inhibits PAF-induced lung inflammatory responses by inhaled administration in guinea pigs.
    International archives of allergy and immunology, 1997, Volume: 114, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Acetylcholine; Animals; As

1997
Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis.
    The European respiratory journal, 2000, Volume: 15, Issue:2

    Topics: Albuterol; Asthma; Bucladesine; Chemotaxis, Leukocyte; Colforsin; Cyclic AMP; Humans; Interleukin-8;

2000
The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs.
    Pulmonary pharmacology & therapeutics, 2000, Volume: 13, Issue:1

    Topics: Acetylcholine; Administration, Inhalation; Airway Resistance; Aminophylline; Animals; Asthma; Bronch

2000
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
    Inflammation, 2000, Volume: 24, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Androstadienes; Animals; Asthma; Beclomethasone; Benzamides; Bu

2000
Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells.
    American journal of respiratory cell and molecular biology, 2000, Volume: 23, Issue:1

    Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagoni

2000
A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects.
    Pulmonary pharmacology & therapeutics, 2000, Volume: 13, Issue:5

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Asthma; Case-Control Studies; Guanidines; Humans;

2000
Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.
    British journal of pharmacology, 2001, Volume: 133, Issue:5

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adolescent; Adult; Allergens; Asthma; CD4-Positive T-Lymphocyte

2001
Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.
    Clinical and experimental immunology, 2001, Volume: 126, Issue:3

    Topics: Adult; Asthma; Cilostazol; Colforsin; Cyclic AMP; Dexamethasone; Humans; In Vitro Techniques; Interl

2001
CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
    Bioorganic & medicinal chemistry letters, 2002, Jun-03, Volume: 12, Issue:11

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-St

2002